By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TRANSGENE S.A. 

11 rue de MOLSHEIM, 67082
Strasbourg
Cedex      France
Phone: 011-33-3-88-27-91-21 Fax: 011-33-3-88-27-91-11


SEARCH JOBS


Industry
Biotechnology

Segment
Gene Therapy

Collaborations

Human Genome Sciences, Inc.  Gene Therapy Partnerships





Company News
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/25/2017 12:38:06 PM
TRANSGENE (ENX:TNG): €50.7 Million In Cash And Cash Equivalents As Of March 31, 2017 4/25/2017 11:48:53 AM
TRANSGENE (ENX:TNG) And Bristol-Myers Squibb (BMY) Announce Clinical Research Collaboration To Evaluate TG4010 In Combination With Opdivo And Standard Chemotherapy In First Line Non-Small Cell Lung Cancer 4/25/2017 6:59:46 AM
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/24/2017 9:57:14 AM
Marie Landel And Maya Said Nominated To Be Independent Members Of TRANSGENE (ENX:TNG)’s Board Of Directors 4/19/2017 12:04:15 PM
TRANSGENE (ENX:TNG) And Institut Bergonié Start The Phase II Part Of METROmaJX Trial 4/12/2017 11:10:22 AM
TRANSGENE (ENX:TNG) Presents Very Promising New Immunology Data Of Its Next Generation Armed Oncolytic Virus At The AACR Annual Meeting In Washington, DC 3/31/2017 7:25:41 AM
TRANSGENE (ENX:TNG) Presents Very Promising New Immunology Data Of Its Next Generation Armed Oncolytic Virus At The AACR Annual Meeting In Washington, DC 3/30/2017 12:55:53 PM
Major Achievements In 2016 Validate TRANSGENE (ENX:TNG)’s Strategy And Provide Promising Outlook For 2017 3/20/2017 10:25:13 AM
First Patient Dosed In Phase 2 Trial Evaluating TRANSGENE (ENX:TNG)’s TG4010 In Combination With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 3/13/2017 11:04:49 AM
12345678910...
//-->